ARTICLE
TITLE

Osteosarcoma de alto grado originado en un tumor filodes maligno

SUMMARY

El tumor filodes maligno con componente estromal (sic) de osteosarcoma es un tumor de muy baja incidencia. La identificación de esta enfermedad se ha convertido en un desafío para la medicina actual debido a su difícil diagnóstico histopatológico, imagenológico y clínico. El tratamiento principal se basa en el manejo quirúrgico, y las opciones de terapia adyuvante aún no presentan un sustento científico sólido para su utilización como tratamiento estándar. Su pronóstico no es bueno. La variante osteoblástica, especialmente, presenta un comportamiento muy agresivo, con un riesgo del 38 % para compromiso metastásico y riesgo de muerte debido a la enfermedad del 33 %. Se presenta el caso de una paciente y se describe cómo se diagnosticó y se trató la enfemerdad.

 Articles related

Hongyang Zhou, Huijie Wu, Meng Li, Chao Dong, Tongyou Sun    

Objectives: To evaluate the clinical efficacy of early postoperative intensity-modulated radiotherapy (IMRT) combined with temozolomide chemotherapy in the treatment of patients with malignant glioma.Methods: In this retrospective cohort study 80 patient... see more


Erwin Danil Yulian, Filipus Dasawala, Nurjati Chairani Siregar    

BACKGROUND Neoadjuvant chemotherapy (NACT) has been shown to improve the overall survival of locally advanced breast cancer (LABC) patients with pathological complete response. However, the efficacy may be reduced due to chemoresistance mediated by P-gly... see more


Lei Ma, Hao Zhang    

Objectives: In this paper, machine learning algorithms was used to explore the application value of ultrasound contrast in the early evaluation of neoadjuvant chemotherapy in patients with gastrointestinal malignant liver metastases, and analyzes the eff... see more


Suresh Pandey    

Background: Limb salvage surgery with or without radiotherapy and/or chemotherapy is the mainstay of treatment of Soft Tissue Sarcoma (STS). Though, many studies are found regarding the demographics and result of such malignancy from other parts of the w... see more


Jasgit C. Sachdev, Jessica N. Snider, Jeffrey W. Allen, Lee S. Schwartzberg, Robyn R. Young, Ahmed Y. Javed, Matthew P. Smeltzer, Furhan Yunus, Carmel S. Verrier, Mohammad Jahanzeb    

Purpose: This phase II neoadjuvant study investigated whether nab paclitaxel, carboplatin and bevacizumab given before neoadjuvant doxorubicin/cyclophosphamide (AC) produced higher pathologic complete response (pCR) rates in triple- negative breast cance... see more